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Since December 2019 the coronavirus disease 2019 (COVID-19) which
emerged in Wuhan, China, has rapidly spread around the globe. With
>10 000 000 confirmed cases in >180 countries and an estimated mor-
tality rate of 2–5%, it has had an enormous economic and social impact
worldwide. Clinical risk factors and diseases which predispose to severe
COVID-19 are pulmonary diseases, advanced age, hypertension, coro-
nary artery disease, diabetes mellitus, and smoking (Figure 1).1 These fac-
tors might affect the susceptibility to infection by the severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) and the subsequent
critical clinical complications.2 Approximately 80% of patients after
SARS-CoV-2 infection develop mild to moderate symptoms, 15% se-
vere, and 5% life-threatening clinical complications. Severe clinical
problems of COVID-19 patients could involve the difficult management
of acute myocardial infarction, acute pulmonary embolism, cardiac tam-
ponade complicating myo-pericarditis, and heart failure.
The infection involves binding of the SARS-CoV-2 spike protein to the
cell receptor angiotensin-converting enzyme 2 (ACE2).3 Because ACE
inhibitors and angiotensin receptor blockers (ARBs) can increase ACE2
expression in experimental studies, this observation has raised discus-
sions about the safety of these important antihypertensive drugs in the
current COVID-19 pandemic.3 It should be emphasized that such dis-
continuation of ACE inhibitor or ARB therapy in patients with heart fail-
ure or coronary disease could lead to unnecessary worsening of cardiac
conditions and hospitalization. Recent position statements from the
European Society of Cardiology (https://www.escardio.org/Councils/
Council-on-Hypertension-(CHT)/News/position-statement-of-the-
esc-council-on-hypertension-on-ace-inhibitors-and-ang), the Eur
opean Society of Hypertension,4 the American Heart Association,
the Heart Failure Society of America, and the American College of
Cardiology (https://www.acc.org/latest-in-cardiology/articles/2020/
03/17/08/59/hfsa-acc-aha-statement-addresses-concerns-re-using-
raas-antagonists-in-covid-19) strongly recommend that patients
taking ACE inhibitors or ARBs who contract COVID-19 should
continue treatment. Recent clinical studies support those
recommendations.5
Statins are well-known and widely prescribed lipid-lowering drugs.
However, statin treatment has increased ACE2 expression in the heart
of experimental models via epigenetic histone modifications.6 This might
raise concerns about the safety of statins in the current COVID-19
pandemic.
From our point of view, up-regulation of ACE2 by statins and ARBs
might even be protective in the pathogenesis of COVID-19. Infection of
experimental models with the closely related SARS-CoV and its spike
protein reduced ACE2 expression. Furthermore, genetic deletion of
ACE2 and ARBs reduced pathological lung alterations after SARS-CoV
infection. A potential mechanism of the protective effects of ARBs during
SARS-CoV infection could be an up-regulation of ACE2. ACE2 usually
mediates the cleavage of angiotensin II into angiotensin(1-7). In contrast
to the classical renin–angiotensin–aldosterone system, the ACE2/
angiotensin(1-7)/Mas receptor axis is considered as protective in the car-
diovascular system, the lung, and the kidney. In addition, statins are vaso-
protective by lowering LDL, up-regulating nitric oxide, and mediating
antioxidative and anti-inflammatory effects. Inflammation plays a major
role in atherosclerosis and cardiovascular diseases.7,8 Statins and ARBs
alone and synergistically improve endothelial function9 and the prognosis
of cardiovascular patients.
The impact of the lipoprotein levels on the clinical outcome in
COVID-19 patients is currently not well understood. Recently, the im-
pact of underlying cardiovascular disease and myocardial injury on fatal
outcomes in patients with COVID-19 has been described.10 This study
compared patients with and without elevation of troponin T (TnT) lev-
els. Total, HDL, and LDL cholesterol levels did not differ between both
groups, but patients with elevated TnT levels showed higher triglyceride
levels. The inflammatory biomarkers high-sensitivity C-reactive protein
*Corresponding author. Division of Vascular Endothelium and Microcirculation, Department of Medicine III, University Hospital Carl Gustav Carus, Technische Universität Dresden,
Fetscherstr. 74, D-01307 Dresden, Germany. Tel: þ49 35 14 58 66 25, Fax: þ49 35 14 58 63 54, Email: Henning.Morawietz@tu-dresden.de
Published on behalf of the European Society of Cardiology. All rights reserved. VC The Author(s) 2020. For permissions, please email: journals.permissions@oup.com.























































































Coronavirus Disease 2019 
(COVID-19)
Severe Acute Respiratory Syndrome Coronavirus 2
(SARS-CoV-2)
80% mild to moderate symptoms
Fever, cough, shortness of breath, fatigue,



























Potential novel therapy: 
Lipoprotein or CRP Apheresis
MyocarditisPneumonia, SARS, septic shock
Hypertension 
CAD
Therapy: Oxygen, antiviral therapy, antibiotics, ventilation, ECMO; treatment of clinical











Figure 1 Conceptional figure highlighting risk factors, clinical characteristics, complications, and therapeutic approaches of severe coronavirus disease 2019
(COVID-19). The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection involves binding to the cell receptor angiotensin-converting en-
zyme 2 (ACE2). Statins, ACE inhibitors, and angiotensin receptor blockers (ARBs) can increase ACE2 expression in experimental studies. This could theoreti-
cally increase viral load (without evidence), but ACE2 up-regulation has been shown to be protective in the cardiovascular system, the lung, and the kidney.
Risk factors for severe COVID-19 are respiratory diseases, advanced age, hypertension, coronary artery disease (CAD), diabetes mellitus, and smoking.
Approximately 80% of COVID-19 patients develop mild to moderate symptoms, 15% severe, and 5% life-threatening clinical complications. They include
pneumonia, severe acute respiratory syndrome (SARS), septic shock, and complications by viral infection in the treatment of CAD, myocardial infarction (MI),
heart failure, myocarditis, and cardiac arrhythmias. Treatment of clinical symptoms according to the guidelines needs preventive measures against SARS-CoV-
2 infections. Prescribed pharmacological therapy including statins should be continued, and novel therapeutic strategies including lipoprotein and CRP aphere-
sis could be tested in clinical studies and documented in European registries. Parts of the figure are adapted from SMART – Servier Medical Art, Servier:
https://smart.servier.com. The SARS-CoV-2 image was created and kindly provided by CDC / Alisa Eckert, MS, and Dan Higgins, MAMS.





















































































































































































































































(hsCRP), procalcitonin, and globulin were significantly increased in
patients with elevated TnT levels. The authors suggest that in patients
with COVID-19, the previous use of cardiovascular drugs should not be
discontinued based on current data. Because SARS and COVID-19
patients are characterized by increased CRP levels and activation of
proinflammatory pathways, statins with their anti-inflammatory potential
might reduce corresponding severe clinical complications of COVID-19-
induced acute lung injury and cardiovascular complications.
Therefore, we would recommend continuing statin therapy in
COVID-19 patients to benefit from its well-documented protective
effects. The statins will control LDL cholesterol levels, thus preventing
lipoprotein-related cardiovascular complications. Immunomodulatory
properties and multiple pleiotropic effects of statins include the inhibi-
tion of T-cell activation, antigen-presenting function, and leucocyte infil-
tration of target organs. They might also protect against myocardial
damage after local inflammation, hypoxia, and ischaemia in response to
severe SARS-CoV-2 infections. Finally, statins could up-regulate the pro-
tective ACE2 in severe lung injury and reduce the impact of inflammation
in the lung, thus supporting beneficial effects. The protective effect of sta-
tins might even be dose dependent. Recently, it was described that sta-
tins may be associated with a lower risk of in-hospital death from
COVID-19 than non-use.5 However, larger clinical trials will be neces-
sary to study the impact of statin therapy on clinical parameters and the
outcome in COVID-19 patients.
Other strategies to lower lipoprotein levels might represent interest-
ing novel therapeutic approaches.11–13 In general, lowering LDL choles-
terol and lipoprotein(a) levels could have beneficial effects such as up-
regulation of ACE2 and prevention of cardiovascular complication dur-
ing COVID-19 infection. The impact of PCSK9 (proprotein convertase
subtilisin/kexin type 9) inhibitors on outcomes of COVID-19 patients is
currently not known. Lipoprotein apheresis is an attractive alternative
therapeutic approach to treat critically ill patients. Lipoprotein apheresis
exerts lipid-lowering effects [especially LDL cholesterol and lipopro-
tein(a)] and anti-inflammatory effects (decrease of CRP and of proinflam-
matory cytokines), and improves the rheological properties of the
blood.14 Because COVID-19 patients have elevated CRP levels and local
inflammation, this therapy might be beneficial. It may contribute to the
stabilization of atherosclerotic plaques which could be affected by the
coronavirus and finally may rupture. Therefore, lipoprotein or even re-
cently described CRP apheresis using rigidly implemented isolation
measures might be a novel strategy in the treatment of COVID-19
patients.
European registries such as the recently created CAPACITY-COVID
registry will be important measures to determine the role of cardiovas-
cular diseases and therapeutic strategies in the COVID-19 pandemic.15
The European Group – International Society for Apheresis (E-ISFA) has
recently joined the German Center for Infection Research, the ESCMID
Emerging Infections Task Force, and a number of other institutions in-
cluding the Robert Koch Institute in the LEOSS (Lean European Open
Survey on SRAS-CoV-s Infected Patients) registry. This is an open, inter-
national, and anonymous registry covering all aspects of COVID-19
infections from diagnosis, laboratory measurements over medical treat-
ments, to clinical outcomes (https://leoss.net). This initiative will help in
defining the impact of apheresis therapy on clinical parameters and out-
comes in COVID-19 patients.
In summary, do not stop the ongoing pharmacological therapy includ-
ing statins and ensure that lipoprotein levels of cardiovascular patients
adhere to the European guidelines in the current COVID-19 pandemic.
Apheresis might represent a promising novel therapeutic approach in se-
verely ill COVID-19 patients. Recently created European registries in-
cluding LEOSS will help to define the role of cardiovascular diseases and
therapeutic strategies in the treatment of COVID-19.
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